Adaptation of clinical pharmacy services to meet patient care needs during the <scp>COVID</scp>‐19 pandemic
Ilya Danelich(AstraZeneca (South Korea)), Cindy J. Wordell(Thomas Jefferson University Hospital), Braden Rall(Thomas Jefferson University Hospital), Geno J. Merli(Thomas Jefferson University), Judith Alberto(Thomas Jefferson University Hospital), Rebecca A. Buckler(Thomas Jefferson University Hospital), Shirley Bonanni(Thomas Jefferson University Hospital), S. Phillips(Thomas Jefferson University Hospital), Lynda Thomson(Thomas Jefferson University Hospital), Brandi Thoma(Thomas Jefferson University Hospital), John J. Foley(Thomas Jefferson University Hospital)
Cited by 8
Related Papers
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
|New England Journal of Medicine|2013|603
2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery
|Journal of the American College of Cardiology|2024|156
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
|Journal of Thrombosis and Thrombolysis|2011|120
D‐dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial
|Journal of Thrombosis and Haemostasis|2014|115